Agennix AG (FRANKFURT: AGX) today announced that the Company will give a corporate presentation at the upcoming Close Brothers Seydler Bank AG Small and Mid Cap Conference. The presentation will be on Thursday, February 4, 2010 at the IHK Frankfurt (Boerse), Frankfurt am Main, Germany.
The Company also announced that it will report its business results for fiscal year 2009 on Wednesday, March 24, 2010. Agennix will hold a conference call to discuss the results and provide a corporate update on that day. Details will be published in advance of the call.

About Agennix

Agennix AG is a publicly traded biopharmaceutical company that is developing novel therapies in areas of major unmet medical need to improve the length and quality of life of seriously ill patients. The Company’s most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Agennix also has recently reported positive results from a Phase 2 trial evaluating talactoferrin in severe sepsis. Other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for diabetic foot ulcers. Agennix is a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas. For additional information, please visit the Agennix Web site at www.agennix.com

Posted: 02|2|10 at 12:17 pm. Filed under: Health Lifestyle.